{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'E', '12. Regional local flow abnormal perfusion defects at baseline PET scan*', '*Note: if contemporary evidence with invasive coronary angiography or CCTA', 'demonstrates non-obstructive coronary arteries or if the regional local flow abnormal', 'perfusion defect on PET scan is consistent with previous studies then patient qualifies for', 'the study.', 'E', '13. Patients with cardiac conduction abnormalities (second or third degree AV block, sick', 'sinus syndrome, symptomatic bradycardia, sinus node disease) except in patients fitted', 'with a functioning pacemaker.', 'E 14. History or known carotid stenosis:', '-', 'Carotid stenosis (>50%)', 'or', '-', 'History of carotid stenosis in patients with previous symptoms.', 'E 15. Contraindication or known hypersensitivity to adenosine or regadenoson.', 'E 16. Contraindication to aminophylline.', 'E 17. Contraindication to vasodilator stress PET scan and/or CCTA if CCTA needed during', 'screening.', 'E 18. Inability to discontinue treatment with methylxanthines treatment within 24 hours prior to', 'PET scan.', 'E 19. Patient unable to read, understand and fill a questionnaire without any help (eg, partially', 'visually impaired or blind).', 'E', '20. Blood donation (blood volume to be defined if needed depending on the country), any', 'volume, within 2 months before inclusion (duration to be checked according to local', 'regulations).', 'E 21. Impossibility to meet specific protocol requirements.', 'E 22. Patient is the Investigator or any Sub-investigator, research assistant, pharmacist, study', 'coordinator, other staff or relative thereof directly involved in the conduct of the protocol.', 'E 23. SBP <110 mmHg at baseline.', 'E 24. Presence at baseline of symptomatic orthostatic hypotension (SBP decrease of 20 mmHg', 'or more at Minute 3 or Minute 5 between seated and standing position), or asymptomatic', 'orthostatic hypotension with a decrease in SBP equal or greater than 30 mmHg at Minute', '3 or Minute 5 when changing from the seated to the standing position.', 'E 25. Renal impairment with estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m\u00b2 at', 'screening and baseline.', 'E 26. Male patient having a female partner of childbearing potential not protected by', 'highly-effective method(s) of birth control (as defined in a local protocol amendment in', 'case of specific local requirement).', 'E 27. Women who are breast feeding.', 'Property of the Sanofi Group - strictly confidential', 'Page 41', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'E 28. Drug-induced liver injury related criteria:', 'Underlying hepatobiliary disease.', 'ALT >3 times the upper limit of normal (ULN).', '7.2.2 Additional exclusion criteria during or at the end of screening before randomization', 'E', '29. Patient who has withdrawn consent before randomization (starting from signed informed', 'consent form).', 'Property of the Sanofi Group - strictly confidential', 'Page 42', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '8', 'STUDY TREATMENTS', '8.1', 'INVESTIGATIONAL MEDICINAL PRODUCT(S) / NON INVESTIGATIONAL MEDICINAL', 'PRODUCT(S)', '8.1.1 INVESTIGATIONAL MEDICINAL PRODUCT(S)', 'Investigational medicinal products:', 'SAR407899, 2.5 mg and 5 mg capsules.', 'SAR407899 matching placebo.', 'Formulation: Capsules.', 'Route and method of administration: Oral administration, twice per day, in the morning and at', 'bedtime, with or without a meal.', 'Dose regimen: 2 capsules in the morning and at bedtime. Dose may be taken with or without food', 'as per preference of the patient.', 'Starting dose:', 'Stopping criterion based on creatinine level:', 'Stop study drug if creatinine level >150 mol/L and increase from baseline >30%. In', 'specific circumstances where creatinine blood level can be obtained only in the afternoon', 'the day of the visit, the patient will be titrated according to titration scheme and if', 'creatinine blood level meets stopping rules, the investigator will need to contact the patient', 'before bedtime intake to permanently discontinue the study drug and schedule a premature', 'study drug discontinuation visit.', 'Property of the Sanofi Group - strictly confidential', 'Page 43', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}